On November 20, 2012, the FDA released its own version of the Sylmar facility inspection report, revealing numerous concerns regarding the design, production, and quality control of the manufacturing process of Durata leads. On this news, St. Jude’s stock price fell $4.34 per share to close at $31.37 per share on November 21, 2012.About Lieff Cabraser
Lieff Cabraser Reminds St. Jude Medical, Inc. Investors Of Upcoming Deadline In Class Action Lawsuits
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.